Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 123 clinical trials
Safety and Efficacy of APG-157 in Head and Neck Cancer

Head & Neck Cancer of oral cavity and/or oropharynx. The study hypothesis is that neoadjuvant use of APG-157 will reduce the tumor burden prior to any definitive therapy to improve the

oral cancer
antineoplastic
carboplatin
squamous cell carcinoma
oropharyngeal
  • 0 views
  • 21 Jul, 2022
  • 2 locations
Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer (ROCOCO)

because reduction of one cycle of chemotherapy can lead to the removal of more tumor burden, compared with three cycles of neoadjuvant chemotherapy. So the investigators aim to compare survival

cytoreductive surgery
cancer antigen 125
ascites
cancer
cancer chemotherapy
  • 45 views
  • 20 Feb, 2022
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

antioxidant found in blueberries or grapes, and it has been shown to be effective in killing tumor cells and reducing cancer burden. It is not yet known whether giving megestrol acetate with or without

total bilirubin
cancer
serum pregnancy test
tumor cells
megestrol acetate
  • 2 views
  • 01 Jul, 2022
  • 1 location
Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

the relapsed setting at a time of high tumor burden and disease resistance.

cyclophosphamide
kidney function test
sarcoma
blood transfusion
platelet count
  • 0 views
  • 21 Jan, 2021
  • 2 locations
CVA Regimen Bridging to HSCT for R/R AL

believed that decreased tumor burden before HSCT is a favorable factor contributing to the long-term survival of R/R AL patients and many kinds of bridging chemotherapy regimens were devised to kill

  • 0 views
  • 03 May, 2022
  • 1 location
PD-1 Antibody and Lenvatinib Plus TACE-HAIC for Potential Resectable HCC: a Single-arm Phase 2 Clinical Trial

-HAIC with PD-1 antibody and lenvatinib, theoretically can significantly decrease the tumor burden and increase the hepatectomy rate. However, this hasn't been verified in clinical application. To

folfox
TACE
  • 0 views
  • 30 Sep, 2021
  • 1 location
Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma

expression in GBM results in increased metabolism of the drug which is detected in the blood or urine of patients with GBM. The levels of acetyl-amantadine captured will be correlated with the tumor burden

  • 0 views
  • 24 Feb, 2021
  • 1 location
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel for Recurrent Glioblastoma (SC9/ABX)

increases chemotherapy concentration in the tumor, and to estimate how effective this treatment is in reducing the tumor burden and prolonging life.

karnofsky performance status
recurrent tumor
glioblastoma multiforme
dexamethasone
recurrent glioblastoma
  • 25 views
  • 14 Jun, 2022
  • 1 location
Women Helping Women - Lung Cancer Screening

to receipt of LDCT in both interventions, with those receiving the Enhanced Intervention more likely to take these steps. Ultimately, such an intervention could lead to a lower lung cancer burden in

cancer
lung cancer
lung cancer screening
lung carcinoma
  • 0 views
  • 29 Nov, 2021
  • 1 location
Efficacy and Safety of Sintilimab With or Without Radiotherapy in Patients With Recurrent or IV NSCLC (EGFR - ALK -) After Failure of Platinum-based Chemotherapy: A Randomized Open Labled Phase II Clinical Study

oligo progression, where irradiation of the thoracic primary lesions can improve the patient's respiratory-related symptoms, reduce the tumor burden, improve the patient's quality of life, and prolong

total bilirubin
cancer
neutrophil count
EGFR
recurrent non-small cell lung cancer
  • 0 views
  • 24 Jan, 2021
  • 1 location